DOCSLIB.ORG

Terminology Drug Development

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

P. de Boer 20-3-2013 Drug Development 1. Drug development is for a well-accepted and New Developments in the demarcated indication that will become part Pharmacological Therapy of of the product label (rather than for a symptom – family of symptoms); Schizophrenia 2. Symptoms may overlap between disease Peter de Boer, PhD categories. It is acceptable to develop Senior Director Experimental Medicine multiple indications but it is generally not Janssen Research and Development acceptable to develop symptom-specific therapies. 3/8/2013 Psychosis Cluster 4 This presentation may contain off-label information or data on investigational compounds. Please always refer to the full product information before prescribing any medicine. Section 1 Views and opinions expressed in this presentation represent those of the presenter and are not necessarily the company. WHY CATEGORIES RATHER THAN DIMENSIONS? 3/8/2013 Psychosis Cluster 2 3/8/2013 Psychosis Cluster 5 Schizophrenia as a disorder of Terminology Frequency cognition (1) Category: An ICD-10/DSM-IV diagnosis (e.g., • Schizophrenia Normal schizophrenia, schizoaffective disorder, Morbid schizotypal personality disorder); Premorbid • Dimension: A symptom or symptom cluster that occurs throughout the population and that, if of sufficient intensity, may lead to a categorical diagnosis (e.g., aberrant sensory experiences); • Symptom: A characteristic sign (e.g., a delusion, IQ Test Score avolition); Impaired Normal High Functioning • Target: A biological process affected by a drug. 3/8/2013 Psychosis Cluster 3 3/8/2013 Psychosis Cluster 6 Nascholing Psychosen 14-15 maart 2013 1 P. de Boer 20-3-2013 Schizophrenia as a disorder of Psychosis: Dimension/Category (2) Frequency cognition (2) Intensity Schizophrenia Psychotic Experiences Schizophrenia Normal 1% Schizotypical Tx A 10% C Normal 1% Test Score 40% 49% Impaired B Normal High Functioning Not strictly continuous variables? 3/8/2013 Psychosis Cluster 7 3/8/2013 Psychosis Cluster 10 Schizophrenia as a disorder of Psychosis in dementia cognition - issues 1. Cognition is a non-specific term; impaired cognitive performance may have diverse causes (= pseudo continuous); 2. Although schizophrenia may be within the family of ‘cognitive disorders’ this does not help with identifying it as a diagnostic entity; 3. Issues may exist in identifying the right target population to treat. Sultzer et al., 2008 Am J Psychiatry 165: 844 – 854 3/8/2013 Psychosis Cluster 8 3/8/2013 Psychosis Cluster 11 Psychosis: Dimension/Category (1) No dopaminergic dysfunction in AD Intensity Schizophrenia Control Parkinson’s Psychotic Experiences 1% Schizotypical 10% Alzheimer’s Dementia /Lewy Normal 40% 49% Not strictly continuous variables? 3/8/2013 Psychosis Cluster 3/8/2013 Psychosis Cluster 12 9 Nascholing Psychosen 14-15 maart 2013 2 P. de Boer 20-3-2013 But psychosis in AD may be related to Implication? neocortical density of neurofibrillary tangles Efficacy of D 2 Neurofibrillary tangle density densities in individuals with antagonists versus without psychosis by brain region (density ± SD [No / Hypothesis: mm2]) DA with w/o Brain region P hyperactivity psychosis psychosis Therapy: A AD in AD? Middle frontal cortex 7.9 (9.7) 2.8 (5.5) .01 Yes Superior temporal Therapy: B 11.9 (15.2) 5.2 (7.9) .008 cortex AD / LBD Therapy Inferior parietal cortex 7.4 (10.0) 4.0 (7.4) .006 No Therapy: C Improved D2R AD / vascular Hippocampus 36.0 (32.6) 26.7 (28.7) .5 modulators Entorhinal cortex 19.3 (18.0) 14.1 (10.1) .3 Observation; Multiple pathological Farber et al. Arch Gen Psychiatry. 2000;57(12):1165-1173. processes 3/8/2013 Psychosis Cluster 13 3/8/2013 16 Psychosis Cluster Risperidone in neuropsychiatric symptom A drug development paradigm based on ‘understanding’ pathophysiological drivers for clusters in dementia psychosis: BPSD population PAD pop. Efficacy Variables RIS-USA-63 RIS-INT-24 RIS-AUS-5 RIS-USA-232 Efficacy of D 2 antagonists 1 mg 2 mg Ris Hal Hypothesis: Behave-AD DA Psychotic Agitation (1) *** *** - ** *** - hyperactivity Psychosis (2) ** * - + ** - Assumption: in AD? Yes Agitation (3) *** *** * *** *** - ‘Classic’ but very localized AD pathology causes NPS Therapy: CMAI Anti-tau No Total Aggression *** *** ** + *** NA Improved D2R Total Non-Aggression * ** - - ** NA modulators Observation: Total *** *** + - *** NA Psychosis BEHAVE-AD: Behavioral Pathology in Alzheimer’s Disease CMAI: Cohen Mansfield Agitation Inventory related to +: 0.05 <p<0.1, after adjusting for multiplicity, as appropriate tangles (1) Subscales A+B+C+D *: p<0.05 (2) Subscales A+B **: p<0.01 (3) Subscales C+D ***: p<0.001 3/8/2013 14 -:173/8/2013 Not significant at 5% level Psychosis Cluster Psychosis Cluster A clinical phenotype of dementia may result from multiple co-existing pathological processes Psychosis: Dimension or Category - conclusions 1. Psychosis as a phenomenon is common in the general population; 2. However, the underlying causes of psychotic experiences are diverse (see example dementia); 3. Hence, the efficacy of a drug against a symptom / symptom cluster in a specific diagnostic category cannot be extrapolated to another diagnostic category without proof. Sweet et al 2004 Neuropsychopharmacology 29 2242 – 2250 3/8/2013 15 3/8/2013 Psychosis Cluster 18 Psychosis Cluster Nascholing Psychosen 14-15 maart 2013 3 P. de Boer 20-3-2013 Preclinical 5955 Correlation D2 occupancy / inhibition of Correlation D2 occupancy / inhibition of apomorphine-induced stereotypy amphetamine-induced hyperlocomotion 100 100 slope: 0.96 ± 0.06 slope: 0.53 ± 0.13 2 2 r : 0.98 clozapine r : 0.76 10 10 clozapine quetiapine quetiapine aripiprazole aripiprazole 1 1 ziprasidone ziprasidone risperidone risperidone 0.1 olanzapine 0.1 olanzapine ED50 Apo. inhibition ED50 haloperidol haloperidol Amph. inhibition ED50 0.01 0.01 0.01 0.1 1 10 100 0.01 0.1 1 10 100 ED50 D2 occupancy ED50 D2 occupancy Correlation D2 occupancy / inhibition of Correlation D2 occupancy / inhibition of Section 3 PCP-induced hyperlocomotion conditioned avoidance response 100 100 slope: 0.61 ± 0.11 r2: 0.87 clozapine clozapine REVIEW OF PROJECTS 10 10 quetiapine quetiapine aripiprazole aripiprazole 1 ziprasidone 1 ziprasidone risperidone risperidone 0.1 olanzapine 0.1 olanzapine slope: 0.76 ± 0.23 haloperidol ED50 PCP inhibition ED50 haloperidol ED50 CAR inhibition ED50 r2: 0.69 0.01 Apo = Apomorphine 0.01 3/8/2013 Psychosis Cluster 19 0.01 0.1 1 10 100 PCP = Phencyclidine 0.01 0.1 1 10 100 ED50 D2 occupancy ED50 = Effective Dose for 50% of maximal effect ED50 D2 occupancy Data on file Clinical At efficacious dose levels Olanzapine blocks 65 - 75% D 2 receptors 3/8/2013 Psychosis Cluster 20 3/8/2013 Psychosis Cluster Data on file 23 Compound Characterization 5955 DA-related – some beliefs. Correlation D2 occupancy / inhibition of Correlation D2 occupancy / inhibition of apomorphine-induced stereotypy amphetamine-induced hyperlocomotion 100 100 slope: 0.96 ± 0.06 681 slope: 0.52 ± 0.15 681 r2: 0.98 646 r2: 0.76 646 1. All currently used antipsychotic medications are 10 10 dopamine D 2 antagonists / weak partial 1 1 agonists; 0.1 0.1 ED50 Apo.inhibition ED50 ED50 Amph. inhibition ED50 0.01 0.01 2. Dopamine systems are well characterized and > 0.01 0.1 1 10 100 0.01 0.1 1 10 100 ED50 D2 occupancy ED50 D2 occupancy 50 years of model development is available to Correlation D2 occupancy / inhibition of Correlation D2 occupancy / inhibition of PCP-induced hyperlocomotion conditioned avoidance response support drug development; 100 100 slope: 0.61 ± 0.11 681 681 r2: 0.87 646 646 3. Hence, demonstration of efficacy of a novel drug 10 10 in a model of dopamine hyperactivity has strong 1 1 predictive validity for clinical efficacy. 0.1 0.1 slope: 0.76 ± 0.23 ED50 PCP inhibition ED50 ED50 CAR ED50 inhibition r2: 0.69 0.01 Apo = Apomorphine 0.01 3/8/2013 Psychosis Cluster 21 3/8/20130.01 0.1 1 10 100 PCP = PhencyclidinePsychosis Cluster 0.01 0.1 1 10 100 24 ED50 D2 occupancy ED50 = Effective Dose for 50% of maximal effect ED50 D2 occupancy Data on file Nascholing Psychosen 14-15 maart 2013 4 P. de Boer 20-3-2013 Clinical pharmacology PDE10 inhibitor In striatum: 70 D1 agonist D2 antagonist 60 10mg JNJ-37822681 bid (Day 14) [JNJ-37822681] 50 plasma 80 calculated striatal D 2 occupancy 80 "conventional" antipsychotic threshold 40 70 70 30 60 60 20 50 OC 50 = 27.1 ng/mL C raclopride displacement 40 50 1 1 10 % 30 0 40 C raclopride dispalcement C raclopride [JNJ-37822681]ng/mL 20 11 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 30 % 10 log 10 [JNJ-37822681] 0 20 0 2 4 6 8 10 12 14 time after dose administration (hours) Nishi et al., 2011 3/8/2013 Psychosis Cluster 25 3/8/2013 Psychosis Cluster 28 5955 Number of subjects included in each treatment group, In vivo , PDE10 inhibitors have a (somewhat) different completers and striatal receptor occupancy throughout the dosing interval as measured with 11 C raclopride PET. behavioral profile compared to a D 2 antagonist Test (acute) PDE10 inhibitor D antagonist Treatment (n) Completers (%) Minimum D Maximum D 2 2 2 Target occupancy ED 1.4 mg/kg po (ex vivo ) ED 0.39 mg/kg sc (in vivo ) bid occupancy (%) occupancy (%) 50 50 (rat striatum) (662 ng/mL plasma) and 6.26 mg/kg sc (ex vivo ) Placebo (24) 100 - - ↓ 1mg/kg APO-stereotypy ED 50 1.3 mg/kg po ED 50 0.194 mg/kg po 10mg JNJ-37822681 (16) 100 43.1 ± 11.2 64.1 ± 11.8 (rat) 20mg JNJ-37822681 (16) 62.5 67.9 ± 6.4 80.7 ± 4.7 ↓ 5mg/kg AMPH-stereotypy ED 50 0.67 mg/kg sc ED 50 0.294 mg/kg sc (rat) 30mg JNJ-37822681 (8) 62.5 71.2 ± 3.0 86.7 ± 2.42 ↓ 1.25 mg/kg AMPH- ED 50 8.2 mg/kg sc ED 50 1.02 mg/kg sc hyperlocomotion (rat) 0.25 4.6 ↓ 1.25 mg/kg PCP- ED 50 2.04 mg/kg sc ED 50 4.7 mg/kg sc The 20 mg bid dose was predicted to provide optimal D2 occupancy in time hyperlocomotion for an antipsychotic effect while the 10 and 30 mg bid doses are too low and high, DA cell firing SN No effect on # neurons/tract Haloperidol: respectively.
Recommended publications
  • (Schizophrenia) – Forecast and Market Analysis to 2022

    (Schizophrenia) – Forecast and Market Analysis to 2022

    REFERENCE CODE GDHC367DFR | PUBLICATION DATE FEBRUARY 2014 BREXPIPRAZOLE (SCHIZOPHRENIA) – FORECAST AND MARKET ANALYSIS TO 2022 BREXPIPRAZOLE (SCHIZOPHRENIA) - FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Table below provides a summary of the key May have an effect on negative symptoms. metrics for Brexpiprazole in the seven major Otsuka has a strong presence in the pharmaceutical markets during the forecast period schizophrenia drug market. upto 2022. Conversely, the major barriers for the growth of Brexpiprazole : Key Metrics in the Seven Major Brexpiprazole in the schizophrenia market include: Pharmaceutical Markets, 2012–2022 Key Events (2012-2022) Level of Impact Higher cost of therapy compared to older Anticipated launch of Brexpiprazole in ↑↑↑ medications. US(2015) Anticipated launch of Brexpiprazole in ↑↑ Requires daily oral dosing. Japan (2016) 2022 Market Sales The figure below illustrates Brexpiprazole sales in US $1,648.9m the 7MM by region during the forecast period. 5EU $28.4m Japan $105.8m Sales for Brexpiprazole by Region, 2022 7MM $1,783.1m 5.9% 1.6% 2022 Source: GlobalData. Total : $1,783.1m 7MM = US, France, Germany, Italy, Spain, UK, Japan; 5EU = France, Germany, Italy, Spain, UK US Sales of Brexpiprazole in Global Schizophrenia 5EU Market, 2022 Japan Brexpiprazole sales are expected to increase from $176.2 million upon launch in 2015 to $1,783.1 92.5% million in 2022. Source: GlobalData. Major growth drivers for Brexpiprazole in the Schizophrenia market over the forecast period include: Structurally similar to Otsuka’s Abilify, the current market leader in the schizophrenia drug market. Improved tolerability and similar efficacy to Abilify demonstrated in clinical trials.
  • FDA Provides New Guidance on Antipsychotic Usage During

    FDA Provides New Guidance on Antipsychotic Usage During

    Clinical News Peter F. Buckley, MD Editor-in-Chief FDA Provides New Guidance on impact of prolonged exposure to antipsychotic medications Antipsychotic Usage during upon total brain volume, as well as both gray matter and Pregnancy caudate-putamen volumes. Modest volumetric reductions were observed. There appeared to be a dose effect of antipsy- The U.S. Food and Drug Administration (FDA), tak- chotics as well. Although the effects were not independent ing stock of all available and new pharmacoepidemiological of other factors that are known to influence potential brain information on antipsychotic medication use, has provided changes—namely, duration of follow-up, illness severity, and updated guidance on prescribing antipsychotics during and comorbid substance abuse—the effect of medications per- immediately after pregnancy. Firstly, the FDA report affirms sisted even when these other influences were taken into ac- the long-held clinical message that untreated psychosis in count statistically. This is a noteworthy observation. the expectant mother is associated with (far) greater risk While the results are still open to other interpretations, than the risks associated with continued use of antipsychot- the observations for this study are sobering. They are also ics. Nevertheless, the report cautions about risks of antipsy- in line with earlier preclinical studies from the University chotic medications for extrapyramidal side effects (EPS) and of Pittsburgh that have demonstrated potential neurotoxic withdrawal side effects in the newborn. The report cites out- effects of antipsychotic medication upon selective neurons. comes for 69 instances of EPS and withdrawal side effects Nevertheless, the “jury is still out” on this contentious top- that were reported to the FDA up until the fall of 2008.
  • A Synthetic Overview of New Molecules with 5-HT1A Binding Affinities

    A Synthetic Overview of New Molecules with 5-HT1A Binding Affinities

    77 A Synthetic Overview of New Molecules with 5-HT1A Binding Affinities Hernán Pessoa-Mahana* 1 ; Ramiro Araya-Maturana1 , Claudio Saitz, B.1 and C. David Pessoa-Mahana2 1Departamento de Química Orgánica y Fisicoquímica. Facultad de Ciencias Químicas y Farmacéuticas. Universidad de Chile. Olivos 1007.Casilla 233. Santiago 1. Chile 2Departamento de Farmacia. Facultad de Química. Pontificia Universidad Católica de Chile. Vicuña Mackenna 4860-Casilla 306, Correo 22 Santiago-Chile Abstract: The present review discusses the synthetic strategies of new ligands exhibiting mainly 5-HT1A binding affinities. Specifically we focused our attention in the synthesis of compounds structurally related to arylpiperazine, 2-aminotetralin, and benzopyran derivatives. Keywords: serotonin, 5-HT1A ligands, arylpiperazines, aminotetralins, benzopyrans. INTRODUCTION During the last 15 years, seven distinct families of 5-HT receptors have been identified (5-HT1–5-HT7), and at least Depression is one of the most common illnesses, 15 subpopulations have been described for several of these affecting up to one-third of all people at the same time. [4,5]. The 5-HT1A receptors represent a major target for Depressive disorders encompass a variety of conditions neurobiological research and drug developments. A study on including two major forms of unipolar depression (i.e. major distribution of 5-HT1A receptors in the brains of various depression and dysthymia), adjustment disorders, animal species indicates that the highest densities are located subsyndromal depression (minor depression), seasonal in the hippocampus, septum, amygdale, and cortical limbic affective disorder (SAD), premenstrual dysphoric disorder areas. The 5-HT1A receptors located in the raphe nuclei are (PMDD), postpartum depression, atypical depression and known as somatodendritic autoreceptors.
  • WO 2016/123576 Al 4 August 2016 (04.08.2016) P O P C T

    WO 2016/123576 Al 4 August 2016 (04.08.2016) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2016/123576 Al 4 August 2016 (04.08.2016) P O P C T (51) International Patent Classification: Unit L, Baltimore, Maryland 21209 (US). WEINBER¬ A61K 31/535 (2006.01) GER, Daniel; 3116 Davenport St. NW, Washington, Dis trict of Columbia 20008-2244 (US). (21) International Application Number: PCT/US2016/015832 (74) Agent: KELLY, Bryte; King & Spalding LLP, 1185 Av enue of the Americas, New York, New York 10036 (US). (22) International Filing Date: 29 January 2016 (29.01 .2016) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (25) Language: English Filing AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (26) Publication Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 62/109,954 30 January 2015 (30.01.2015) US KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (71) Applicant: LIEBER INSTITUTE FOR BRAIN DE¬ MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, VELOPMENT [US/US]; 855 North Wolfe Street, Suite PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 300, 3rd Floor, Baltimore, Maryland 21205 (US). SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
  • Davey KJ Phd 2013.Pdf

    Davey KJ Phd 2013.Pdf

    UCC Library and UCC researchers have made this item openly available. Please let us know how this has helped you. Thanks! Title The gut microbiota as a contributing factor to antipsychotic-induced weight gain and metabolic dysfunction Author(s) Davey, Kieran Publication date 2013 Original citation Davey, K. 2013. The gut microbiota as a contributing factor to antipsychotic-induced weight gain and metabolic dysfunction. PhD Thesis, University College Cork. Type of publication Doctoral thesis Rights © 2013. Kieran Davey http://creativecommons.org/licenses/by-nc-nd/3.0/ Embargo information Restricted to everyone for one year Item downloaded http://hdl.handle.net/10468/1243 from Downloaded on 2021-10-09T20:00:22Z Ollscoil na hEireann National Unversity Ireland Colaiste na hOllscoile, Corcaigh University College Cork School of Pharmacy The Gut Microbiota as a Contributing Factor to Antipsychotic-Induced Weight Gain and Metabolic Dysfunction Thesis presented by Kieran J. Davey under the supervision of Prof. John F. Cryan Prof. Timothy G. Dinan Dr Siobhain M. O’Mahony for the degree of Doctor of Philosophy Head of School: CatrionaO’Driscoll Contents Declaration ........................................................................................................................................... vii Acknowledgements .......................................................................................................................... viii Publications and presentations .....................................................................................................
  • Achat Viagra Puissant ### Ablation Prostate Et Viagra &gt;&gt;&gt; Kvadridze.Github.Io

    Achat Viagra Puissant ### Ablation Prostate Et Viagra >>> Kvadridze.Github.Io

    Viagra est indiquée pour le traitement de la dysfonction érectile masculine. >>> ORDER NOW <<< Achat viagra puissant Tags: ordonnance de viagra combien de temps dur viagra comment peut on se procurer du viagra efficacité viagra générique un site fiable pour acheter du viagra le viagra sur ordonnance danger dacheter du viagra sur internet prix cachet viagra combien coute le viagra au maroc le rôle de viagra peut acheter du viagra sans ordonnance quesque cest viagra composition de viagra acheter viagra paris sans ordonnance comment se procurer viagra sans ordonnance comment reconnaitre le faux viagra quand faut il prendre viagra comment acheter du viagra au quebec lancement du viagra quest ce que cest le viagra viagra pfizer mode demploi les conséquences du viagra edex plus viagra comment prendre de viagra forum viagra pas cher commande de viagra en ligne meme effet que viagra prendre la moitié dun viagra experience viagra femme A vaginal ring can slip out of the vagina. In the event of overdosage, general symptomatic and achat viagra puissant measures are indicated as required Resistance to azithromycin may be inherent or acquired. Comments: Take one pill a day. Ca 20 minuter senare börjar mina kollegor droppa in i ordningen: Susanne, Britt, Emma, Nina, Gunnel, Eva och sist Barbro. Epidemiologic investigations of this outbreak demonstrated that individuals in close contact with the index case or with exposure to poultry were at risk of being infected. 25 mg pour femme viagra cherche 2 weeks or until I "felt" like I could go lower. It might take a while to adapt to it, since it will lower your blood pressure.
  • Current Topics in Medicinal Chemistry, 2016, 16, 3385-3403 REVIEW ARTICLE

    Current Topics in Medicinal Chemistry, 2016, 16, 3385-3403 REVIEW ARTICLE

    Send Orders for Reprints to [email protected] 3385 Cur rent Topics in Medicinal Chemistry, 2016, 16, 3385-3403 REVIEW ARTICLE ISSN: 1568-0266 eISSN: 1873-5294 Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Impact Factor: 2.9 The international Present and Future journal for in-depth reviews on Current Topics in Medicinal Chemistry BENTHAM SCIENCE Peng Li*, Gretchen L. Snyder and Kimberly E. Vanover Intra-Cellular Therapies Inc, 430 East 29th Street, Suite 900, New York, NY 10016, USA Abstract: Schizophrenia is a chronic and debilitating neuropsychiatric disorder affecting approxi- mately 1% of the world’s population. This disease is associated with considerable morbidity placing a major financial burden on society. Antipsychotics have been the mainstay of the pharmacological treatment of schizophrenia for decades. The traditional typical and atypical antipsychotics demon- strate clinical efficacy in treating positive symptoms, such as hallucinations and delusions, while are A R T I C L E H I S T O R Y largely ineffective and may worsen negative symptoms, such as blunted affect and social withdrawal, as well as cognitive function. The inability to treat these latter symptoms may contribute to social Received: April 07, 2016 Revised: May 20, 2016 function impairment associated with schizophrenia. The dysfunction of multiple neurotransmitter Accepted: May 23, 2016 systems in schizophrenia suggests that drugs selectively targeting one neurotransmission pathway DOI: 10.2174/1568026616666160608 are unlikely to meet all the therapeutic needs of this heterogeneous disorder. Often, however, the un- 084834 intentional engagement of multiple pharmacological targets or even the excessive engagement of in- tended pharmacological targets can lead to undesired consequences and poor tolerability.
  • Annual Report 2011 3) the Calculation Is Based on a Share Denomination of DKK 5

    Annual Report 2011 3) the Calculation Is Based on a Share Denomination of DKK 5

    Financial highlights Group 2011 2010 2009 2008 2007 2011 2011 DKKm DKKm DKKm DKKm DKKm EURm1 USDm2 Revenue 16,007 14,765 13,747 11,572 11,171 2,148 2,987 Research and development costs 3,320 3,045 3,196 2,990 2,193 446 620 Operating profit before depreciation and amortisation (EBITDA) 4,628 4,393 3,728 3,418 3,611 621 864 Profit from operations (EBIT) 3,393 3,357 2,858 2,354 2,689 455 633 Net financials (96) (68) (192) (28) 65 (13) (18) Profit for the year 2,282 2,466 2,007 1,663 1,881 306 426 Total assets 20,534 18,005 17,127 12,526 12,230 2,762 3,574 Equity 12,776 11,122 8,803 7,511 7,089 1,719 2,224 Cash flows from operating and investing activities 929 2,462 (2,040) 2,193 1,610 125 173 Investments in property, plant and equipment, gross 419 383 258 229 474 56 73 % % % % % % % EBITDA margin 28.9 29.8 27.1 29.5 32.3 28.9 28.9 EBIT margin 21.2 22.7 20.8 20.3 24.1 21.2 21.2 Return on capital employed 25.3 27.6 28.0 30.0 34.6 25.3 25.3 Return on equity 19.1 24.8 24.6 22.8 27.3 19.1 19.1 Research and development ratio 20.7 20.6 23.2 25.8 19.6 20.7 20.7 Solvency ratio 62.2 61.8 51.4 60.0 58.0 62.2 62.2 Capital turnover 78.0 82.0 80.3 92.4 91.3 78.0 78.0 Effective tax rate 30.8 25.0 24.7 27.1 29.6 30.8 30.8 DKK DKK DKK DKK DKK EUR1 USD2 Earnings per share (EPS)3 11.63 12.57 10.24 8.45 9.18 1.56 2.17 Diluted earnings per share (DEPS)3 11.63 12.57 10.24 8.45 9.17 1.56 2.17 Proposed dividend per share3 3.49 3.77 3.07 2.30 2.56 0.47 0.65 Cash flow per share3 18.48 16.65 15.47 14.12 13.18 2.48 3.45 Net asset value per share3 65.14 56.71 44.89
  • Marrakesh Agreement Establishing the World Trade Organization

    Marrakesh Agreement Establishing the World Trade Organization

    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
  • Drug Delivery System for Use in the Treatment Or Diagnosis of Neurological Disorders

    Drug Delivery System for Use in the Treatment Or Diagnosis of Neurological Disorders

    (19) TZZ __T (11) EP 2 774 991 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 10.09.2014 Bulletin 2014/37 C12N 15/86 (2006.01) A61K 48/00 (2006.01) (21) Application number: 13001491.3 (22) Date of filing: 22.03.2013 (84) Designated Contracting States: • Manninga, Heiko AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 37073 Göttingen (DE) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO •Götzke,Armin PL PT RO RS SE SI SK SM TR 97070 Würzburg (DE) Designated Extension States: • Glassmann, Alexander BA ME 50999 Köln (DE) (30) Priority: 06.03.2013 PCT/EP2013/000656 (74) Representative: von Renesse, Dorothea et al König-Szynka-Tilmann-von Renesse (71) Applicant: Life Science Inkubator Betriebs GmbH Patentanwälte Partnerschaft mbB & Co. KG Postfach 11 09 46 53175 Bonn (DE) 40509 Düsseldorf (DE) (72) Inventors: • Demina, Victoria 53175 Bonn (DE) (54) Drug delivery system for use in the treatment or diagnosis of neurological disorders (57) The invention relates to VLP derived from poly- ment or diagnosis of a neurological disease, in particular oma virus loaded with a drug (cargo) as a drug delivery multiple sclerosis, Parkinsons’s disease or Alzheimer’s system for transporting said drug into the CNS for treat- disease. EP 2 774 991 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 774 991 A1 Description FIELD OF THE INVENTION 5 [0001] The invention relates to the use of virus like particles (VLP) of the type of human polyoma virus for use as drug delivery system for the treatment or diagnosis of neurological disorders.
  • Novel Implications for Lost Serotonin Transporter Function on Platelet

    Novel Implications for Lost Serotonin Transporter Function on Platelet

    Novel implications of lost serotonin transporter function on platelet biology By Kendra Helen Oliver Dissertation Submitted to the Faculty of the Graduate School of Vanderbilt University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in Pharmacology December, 2016 Nashville, Tennessee Approved: Date: _______________________________________________ __________________ Jonathan Schoenecker, M.D., Ph.D. (Chair) _______________________________________________ __________________ Heidi E. Hamm, Ph.D. _______________________________________________ __________________ Ana M.D. Carneiro, Ph.D. _______________________________________________ __________________ Digna R. Velez Edwards Ph.D., M.S. _______________________________________________ __________________ Vsevolod Gurevich, Ph.D. DEDICATION To my parents, Michael Cherry and Kimberlee Oliver, to my brilliant sister, Briana Oliver, and to my partner in crime, Dr. Max Joffe. ii ACKNOWLEDGEMENTS There are so many wonderful people that have I would like to thank for their support and guidance during this challenging and daunting process. Most importantly, I would like to thank my mentors, Dr. Heidi E Hamm and Dr. Ana M.D. Carneiro. Dr. Carneiro has pushed me beyond my limits and has provided my scholarly foundation. Dr. Hamm has also been an outstanding mentor and role model as a scientist. I would also like to thank my committee members for their guidance during my scientific scholarship. The direction and administrative support received from Dr. Christine Konrodi and Karen Geig, and Dr. Joey Barrett, has been extraordinary, and for that I am very thankful. Additionally, I would like to thank and acknowledge my lab members. In particular, Dr. Matthew Duvernay has helped me navigate the world of platelet biology and Dr. Ali Kali for his support and encouragement.